Advertisements

Cifran 500 mg

Quick links to important sections

Cifran 500 mg

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Cifran 500 mg

Quick Facts: Cifran 500 mg

Property Description
Active ingredient Ciprofloxacin
Form Film-coated tablet
Pharmacological class Antibiotic (Fluoroquinolone)
Common use Systemic treatment of bacterial infections
Origin Synthetic compound

What Type of Medicine is Cifran 500 mg?

Cifran 500 mg is a specific synthetic medicinal product, recognized globally as a potent antibiotic and classified within the Fluoroquinolone family. This formulation, often associated with specific manufacturers, is consistently supplied as a prescription-only (Rx) product, underlining its powerful systemic action and the need for medical oversight during treatment. Ciprofloxacin, the active agent, is used in treating bacterial infections. Its classification as a Fluoroquinolone distinguishes it as a highly active, broad-spectrum agent used for targeted pathogen clearance.

Composition and Form of Cifran 500 mg Tablets

The therapeutic action of Cifran 500 mg is derived solely from its single active ingredient, Ciprofloxacin (or Ciprofloxacin hydrochloride). The drug is formulated as a precise, film-coated tablet intended for oral administration. The "500 mg" designation denotes the standard dose strength of Ciprofloxacin in this specific presentation. This concentration is used for initiating systemic treatment, distinguishing it from lower or higher strength Ciprofloxacin forms. This ensures that the medicine is manufactured to deliver a consistent and verified therapeutic dose.

What is the General Purpose of a Fluoroquinolone Antibiotic?

The fundamental purpose of Cifran 500 mg is to exert bactericidal action, meaning it is specifically designed to kill bacterial organisms, rather than merely inhibiting their reproduction. This decisive action is crucial in cases requiring the complete eradication of the pathogen. Ciprofloxacin's chemical action involves the inhibition of bacterial DNA gyrase and topoisomerase IV. This facilitates the drug’s mechanism as a method for achieving bacterial clearance and resolving the underlying bacterial infection.

Regulatory References

  1. FDA Label (Ciprofloxacin)
  2. NIH Review (Ciprofloxacin)
Advertisements

What side effects are possible with Cifran 500 mg?

Official Safety Profile

Regulatory authorities classify the safety profile of Cifran (Ciprofloxacin) by key adverse reaction categories, frequencies, and mandatory warnings.

Serious and Potentially Irreversible Risks

Official labels contain the most severe warnings, including the risk of disabling and potentially irreversible serious adverse reactions affecting the tendons, peripheral nerves, and the central nervous system (CNS).

  • Tendons: Tendinitis and tendon rupture (most commonly Achilles tendon) can occur during treatment or up to several months after discontinuation.
  • Nerves: Peripheral neuropathy (nerve damage) may involve symptoms like numbness, tingling, or burning pain, which may become permanent.
  • CNS: Serious CNS effects include seizures, increased intracranial pressure, psychosis, confusion, and suicidal thoughts.
  • Other Severe Risks: The drug is also associated with a risk of Aortic Aneurysm and Dissection, serious liver injury (hepatotoxicity), severe hypersensitivity reactions (including anaphylaxis), and exacerbation of muscle weakness in patients with Myasthenia Gravis.

Common Adverse Reactions

These side effects are those most frequently reported in clinical trials, classified as common (ge 1/100 to < 1/10):

  • Nausea
  • Diarrhea
  • Headache
  • Dizziness
  • Vomiting

Safety Restrictions and Limitations

The medicine is restricted for use in patients with certain infections if there are no alternative treatment options due to the risk of serious side effects. It is also contraindicated in patients with a history of hypersensitivity to the drug or other quinolones, and for concomitant use with Tizanidine. Patients with kidney impairment require dosage adjustments, and its use is restricted in pediatric patients due to the risk of musculoskeletal disorders.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation details the potential manifestations and required emergency actions associated with Cifran 500 mg (Ciprofloxacin) overdose.

Documented Manifestations

Overdose may be associated with various effects on the Central Nervous System (CNS), including dizziness, tremor, confusion, hallucinations, and the potential for seizures. Gastrointestinal effects such as nausea and vomiting are also possible. Specific findings related to the kidneys include the presence of crystalluria and the risk of developing acute reversible renal failure. Patients with pre-existing renal impairment may face an increased risk of toxicity in an overdose scenario due to reduced drug clearance.

Required Emergency Actions

The official labeling mandates that immediate medical attention must be sought for any suspected overdose. This action is critical because no specific antidote is known to reverse the effects of Ciprofloxacin overdose. Management is limited to symptomatic and supportive treatment.

Regulatory documents describe procedural steps such as the administration of activated charcoal or gastric lavage if performed shortly after ingestion. Furthermore, maintaining adequate hydration is specifically recommended to help mitigate the risk of crystalluria, and monitoring of renal function and ECG may be required due to documented risks.

Advertisements

Therapeutic Uses of Cifran 500 mg

What Cifran 500 mg Treats: Main Uses and Benefits

Cifran 500 mg is commonly used for managing various illnesses associated with bacterial infections. Its primary benefit is to provide support that assists in eliminating the bacteria, which contributes to easing the overall symptom load.

The medication is relevant for easing discomfort linked to organ-specific functional stress and helps address symptom clusters that may become intense or disruptive in conditions characterized by periods of heightened symptoms. It is commonly used for infections of the urinary tract, respiratory tract, skin, bone, and joints.

In these acute scenarios, Cifran 500 mg offers symptomatic relief that helps patients cope more steadily with difficult episodes. It is commonly applied in clinical settings that involve sudden, disruptive symptom patterns, such as painful urination, persistent cough, or localized swelling due to infection, assisting with maintaining functional stability in these areas.

“The treatment is relevant for managing symptoms that interfere with daily comfort and create noticeable functional strain.”


Quick Fact: Relief for Systemic Discomfort

Cifran 500 mg assists in managing symptoms related to systemic imbalance, such as fever and malaise, which are common manifestations of active bacterial illness.

Regulatory References

  1. NIH MedlinePlus overview of Ciprofloxacin
Advertisements

Eligibility and Restrictions for Use

Cifran 500 mg (ciprofloxacin) is a fluoroquinolone antibiotic. Its use is subject to specific restrictions and contraindications as defined by official regulatory authorities. Contraindications define populations that must not use this medicine under any circumstances, while Restrictions outline patient groups who require special caution or for whom use is limited.

Populations Who Must Not Use Cifran (Contraindications)

  • Known Hypersensitivity: Individuals with a documented allergy to ciprofloxacin, any other fluoroquinolone/quinolone antibiotic, or any ingredient in the tablet.
  • Concomitant Tizanidine Use: Patients who are simultaneously taking the muscle relaxant tizanidine, as this combination is strictly prohibited.

Populations Requiring Restricted or Cautious Use

Patient Group Eligibility Status Regulatory Constraint
Pediatric Patients (Under 18) Restricted Use Generally not recommended due to risk of joint/musculoskeletal damage; use is reserved for specific severe infections (e.g., complicated UTIs, anthrax).
Myasthenia Gravis Use Must Be Avoided May exacerbate muscle weakness in patients with a known history of this condition.
QT Prolongation/Hypokalemia Avoid Use/Caution Patients with known QT interval prolongation or uncorrected low potassium levels (hypokalemia) should avoid use.
Pregnancy and Lactation Avoided / Not Recommended Safety and effectiveness have not been definitively established; use is generally avoided during pregnancy and breastfeeding is not recommended.
Geriatric Patients (ge 60 years) Caution Required Increased risk of serious tendon disorders and potential for effects on the heart's electrical rhythm (QT prolongation).
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Cifran 500 mg (Ciprofloxacin) strictly defines co-administration constraints based on pharmacokinetic effects and absorption interference. The regulatory profile mandates the absolute prohibition of co-administration with Tizanidine, as Ciprofloxacin’s potent inhibition of the CYP450 1A2 enzyme significantly increases Tizanidine plasma exposure.

Documented Pharmacokinetic and Absorption Constraints

Interaction Mechanism Interacting Substances/Category Official Restriction/Outcome
CYP1A2 Inhibition Theophylline, Caffeine, Ropinirole Decreases clearance, resulting in elevated serum concentrations of co-administered drug.
Chelation Complex Formation Multivalent Cation-Containing Products (e.g., Antacids, Iron, Magnesium, Zinc supplements) Significantly reduces Ciprofloxacin absorption; mandatory timing separation required.
Renal Secretion Inhibition Probenecid, Methotrexate Increases Ciprofloxacin serum concentrations (Probenecid) or potentially increases co-administered drug levels (Methotrexate).
Additive Pharmacodynamic Effect Drugs that prolong the QT interval Caution advised due to the potential for an additive effect on the QT interval.

All multivalent cation-containing products must be administered at least 2 hours before or 6 hours after the Ciprofloxacin dose to prevent this interaction. Ciprofloxacin is not affected by dietary calcium consumed as part of a meal. Co-administration with Warfarin may enhance the anticoagulant effect and requires official regulatory notice.

Advertisements

Mechanism of Action

️ Molecular Mechanism: The Bactericidal Action of Ciprofloxacin

The mechanism of Cifran 500 mg is defined by its selective and lethal intervention within the bacterial cell. The active agent, Ciprofloxacin, functions as a topoisomerase poison, primarily targeting two bacterial-specific enzymes essential for maintaining DNA structure: DNA Gyrase (Topoisomerase II) and Topoisomerase IV.

Ciprofloxacin binds to and stabilizes the DNA-enzyme cleavage complex inside the bacterial cell. This action prevents the enzyme from resealing the transient cuts it makes in the DNA strands, effectively converting those temporary cuts into permanent double-strand DNA breaks.

This unresolvable genomic damage initiates a rapid and irreversible intracellular cascade that leads to the complete shutdown of replication and transcription pathways. The resulting physiological effect is bactericidal action—the definitive killing of susceptible bacterial organisms.

However, this mechanism is physiologically constrained if bacteria possess efflux pumps that actively expel the drug, or if gene mutations reduce the drug's binding affinity at the target sites, thereby reducing the mechanism's activity.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

The usage of Cifran 500 mg, which contains ciprofloxacin, is governed by principles detailed in official documentation. The product is available as a film-coated tablet for oral administration, though an intravenous (IV) solution exists for more severe clinical scenarios.

The standard adult dosing schedule for the immediate-release tablet typically ranges from 250 mg to 750 mg per dose and is generally administered twice daily (every 12 hours) to maintain a consistent systemic concentration. The duration of therapy is highly variable, ranging from short courses of 3 days for certain uncomplicated conditions to up to 60 days for specific prophylactic uses. Patients are officially instructed to use the medicine for the full length of the prescribed course.

Practical Administration Conditions

Condition Official Use Principle
Food and Fluid Intake The tablet may be taken with or without food but requires consumption with plenty of fluids. It must not be taken alone with milk, yogurt, or calcium-fortified juice.
Cation Separation The dose must be separated from antacids, sucralfate, iron supplements, and other mineral-containing products by at least 2 hours before or 6 hours after the mineral product.
Population Adjustment Dose reductions and interval extensions are officially mandated for patients with renal impairment to prevent excessive accumulation of the drug. Pediatric dosing for approved uses is calculated on a weight-based (mg/kg) regimen.

The consistent, twice-daily schedule and mandatory separation from metal-containing substances are procedural steps designed to ensure appropriate drug absorption and systemic delivery as defined by established protocols.

Advertisements

Recent Clinical Evidence

Cifran 500 mg: Recent Clinical Evidence


Overview of Clinical Research

Cifran (ciprofloxacin) is a widely used fluoroquinolone antibiotic. Clinical research has explored its role in treating a variety of bacterial infections, including those affecting the urinary tract, respiratory system, skin, and bone and joints. Study designs have included randomized controlled trials and large-scale safety monitoring.

Efficacy and Outcome Measures

Clinical trials have consistently focused on evaluating the medication's effect on infection clearance and patient recovery.

  • Urinary Tract Infections (UTIs): Studies often use the 500 mg twice-daily dosage for complicated UTIs and pyelonephritis (kidney infection). Evidence from various trials indicates a high rate of favorable clinical and bacteriological responses in managing these infections.
  • Lower Respiratory Tract Infections (LRTIs): Research has examined the use of Cifran 500 mg twice daily for conditions such as acute exacerbations of chronic bronchitis and pneumonia caused by susceptible pathogens. Clinical response rates have been reported to be favorable in a majority of evaluated courses of therapy.

Safety and Tolerability Profile

Safety data is drawn from extensive worldwide clinical exposure. Findings consistently report the side-effect profile of ciprofloxacin. The most frequently observed adverse events are typically related to the gastrointestinal system (e.g., nausea, diarrhea) and the central nervous system (e.g., headache).

  • Specific Populations: Retrospective analyses have compared the safety profile of ciprofloxacin in patients aged 65 and older versus younger adults. The findings did not show a clinically significant difference in the incidence of adverse events between the two age groups.
  • Serious Risks: Regulatory guidance emphasizes that due to the potential for serious side effects, including tendon issues and central nervous system effects, ciprofloxacin is generally reserved for use when safer alternative antibiotics are not suitable.

Key Studies & References

  1. Ciprofloxacin - StatPearls - NCBI Bookshelf
  2. Efficacy and safety of ciprofloxacin treatment in urinary tract infections (UTIs) in adults: a systematic review with meta-analysis
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Cifran 500 mg (FAQ)


Q: Is there information about taking Cifran 500 mg with common pain relief medications?

Official guidance indicates that no interactions have been found between ciprofloxacin and the common pain reliever paracetamol (acetaminophen). However, regulatory documents highlight that ciprofloxacin can interact with certain other medications sometimes used for pain or inflammation, such as steroids or methotrexate. It is important that a healthcare professional is aware of all medicines being used to appropriately manage potential interactions.


Q: Is Cifran 500 mg considered to be a strong antibiotic?

Official product information describes Cifran (ciprofloxacin) as a potent broad-spectrum antimicrobial agent. The term broad-spectrum means it is designed to be effective against a wide range of different bacterial types. This classification reflects its wide activity range compared to certain older antibiotics.


Q: What are the high-level research themes regarding Cifran 500 mg resistance?

Research themes on resistance focus on the unique mechanism of this drug class. Official documents note that because Cifran's action is different from older antibiotic classes like penicillin, bacteria that are resistant to those older medicines may still be susceptible to ciprofloxacin. This forms part of the regulatory context when determining appropriate use for certain infections.


Q: How is Cifran 500 mg different from Azithromycin in its function?

Cifran (ciprofloxacin) is classified as a fluoroquinolone antibiotic, which works by directly killing bacteria through the inhibition of bacterial DNA enzymes. In contrast, Azithromycin is a macrolide antibiotic, which typically functions by stopping bacteria from reproducing by disrupting their ability to create essential proteins. They belong to different drug classes and work in distinct ways.


Q: What does the term 'broad-spectrum' mean in relation to Cifran 500 mg?

The term broad-spectrum is used to classify Cifran (ciprofloxacin) as an antimicrobial agent that is effective against a wide range of different bacterial organisms. Official product information indicates it has activity against both gram-negative and gram-positive microorganisms.


Q: Are there common signs of an allergic reaction to Cifran 500 mg?

Official safety guidance indicates that common signs of an allergic reaction may include an unusual skin reaction, such as a swollen, raised, itchy, blistered, or peeling rash. Any sign of a severe allergic reaction is addressed in the product's official safety information, which states that symptoms can escalate to include difficulty breathing or swelling of the face.


Q: How quickly can a person generally expect Cifran 500 mg to begin working?

According to the official pharmacological data, Cifran (ciprofloxacin) is rapidly and well absorbed into the body after it is taken orally. The maximum concentration of the drug in the bloodstream is typically reached within 1 to 2 hours after an oral dose. This indicates the time it takes for the drug's active substance to reach its highest level in the body.


Q: Can Cifran 500 mg cause sensitivity to sunlight?

Yes, official safety information indicates that this medication can increase a person's sensitivity to the sun, a side effect known as photosensitivity. Regulatory guidance includes information that staying out of direct sunlight and using protective measures, such as wearing sunscreen and a hat, may be necessary while using this medicine.


Q: What type of research has been conducted on the long-term use of Cifran 500 mg?

The safety data reviewed by regulatory bodies highlights concerns related to the potential for serious, disabling, and long-lasting side effects that may not resolve. These serious adverse events, which involve the tendons, peripheral nerves, and the central nervous system, have been reported to occur months or years after the drug has been discontinued.


Q: What are the official recommendations about driving while using Cifran 500 mg?

Official patient guidance states that Cifran may affect a person's coordination, reaction time, or judgment. Due to this possibility, official guidance typically suggests that patients do not drive or operate heavy machinery until they are aware of how the medication affects their individual ability to perform these tasks.


Q: How long does Cifran 500 mg typically remain in the body after the last dose?

For individuals with normal kidney function, the official pharmacological data shows that Cifran has a serum elimination half-life of approximately 4 hours. Generally, a drug's elimination is based on its half-life, and official data indicates the substance is largely processed by the body within 20 to 24 hours.


Q: Are there concerns about Cifran 500 mg affecting blood sugar levels?

Official drug safety communications indicate that Cifran, which belongs to the fluoroquinolone class, is associated with a risk of blood sugar disturbances. This can include instances of dangerously low blood sugar (hypoglycemia), particularly in older individuals.


Q: Does official guidance say anything about drinking alcohol while on Cifran 500 mg?

Official regulatory guidance does not contain a specific contraindication (a direct ban) against combining alcohol with ciprofloxacin. However, alcohol consumption may worsen common side effects of the drug such as nausea, dizziness, or drowsiness.


Q: Is Cifran 500 mg a treatment for ear infections?

Ciprofloxacin, the active ingredient in Cifran, is used to treat ear infections. However, this is typically managed using a different pharmaceutical formulation, such as ear drops (otic route), rather than the oral tablet form of Cifran 500 mg.


Q: Does Cifran 500 mg interact with herbal supplements?

Official health guidance states that there is often not enough clinical information available to confirm whether most complementary or herbal remedies are safe to take while using ciprofloxacin. Regulatory guidance often suggests that all supplements being taken should be communicated to a healthcare professional.


Q: What is the role of Cifran 500 mg in treating chronic conditions?

Cifran (ciprofloxacin) is approved for the treatment of various bacterial infections, including certain conditions that may be chronic. For instance, regulatory documents confirm its use in the treatment of Chronic Bacterial Prostatitis. Its use in other acute or chronic infections is determined by health guidelines.


Q: Does Cifran 500 mg interact with birth control pills?

Official clinical guidance indicates that ciprofloxacin may reduce the effectiveness of ethinyl estradiol, a common ingredient found in some birth control pills. This interaction may increase the risk of pregnancy or cause breakthrough bleeding for some individuals.


Q: What is the official stance on using Cifran 500 mg for travellers' diarrhea?

Official regulatory labeling includes Cifran (ciprofloxacin) as an approved treatment for Infectious Diarrhea, which covers cases of traveller's diarrhea. The approved use and duration of therapy for this indication are detailed in the official product information.

Advertisements

How should Cifran 500 mg be stored and disposed of?

How to Store and Dispose of Cifran 500 mg?

Cifran 500 mg (ciprofloxacin) tablets must be handled according to specific regulatory requirements to maintain product stability and ensure safety.


Storage Requirements

Cifran 500 mg must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept out of the sight and reach of children to prevent accidental ingestion. Do not use the tablets after the expiry date printed on the packaging.


Disposal Instructions

Unused or expired Cifran 500 mg product must be returned to a pharmacist or an approved collection point for safe disposal. It is officially mandated that the medicine and its container must not be disposed of via wastewater (flushing down the toilet or sink) or with household waste (trash).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cifran 500 mg found in:

A-Z Index: